scholarly article | Q13442814 |
P356 | DOI | 10.1111/J.1440-1746.2004.03370.X |
P698 | PubMed publication ID | 15304120 |
P2093 | author name string | Hiroshi Sato | |
Jun Araki | |||
Makoto Kuroda | |||
Keisuke Takeuchi | |||
Tomoaki Ishihara | |||
Yoshinao Kobayashi | |||
Yukihiko Adachi | |||
Yoshihiro Maruo | |||
Shigenori Tamaki | |||
Masahiko Kaito | |||
Rumi Mifuji | |||
Toshio Itani | |||
P2860 | cites work | Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? | Q24670527 |
Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype | Q28140057 | ||
Inherited disorders of bilirubin metabolism | Q28217356 | ||
Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2 | Q28258092 | ||
Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II | Q28258225 | ||
Molecular genetic basis of Gilbert's syndrome | Q33756586 | ||
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome | Q34057969 | ||
Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome | Q34374626 | ||
Altered coding for a strictly conserved di-glycine in the major bilirubin UDP-glucuronosyltransferase of a Crigler-Najjar type I patient | Q36715577 | ||
P433 | issue | 9 | |
P921 | main subject | Crigler-Najjar syndrome | Q1140000 |
P304 | page(s) | 1023-1028 | |
P577 | publication date | 2004-09-01 | |
P1433 | published in | Journal of Gastroenterology and Hepatology | Q15764401 |
P1476 | title | Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. | |
P478 | volume | 19 |
Q44767175 | A genome-wide search for non-UGT1A1 markers associated with unconjugated bilirubin level reveals significant association with a polymorphic marker near a gene of the nucleoporin family |
Q33283468 | Adaptive evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymes |
Q92999855 | Analysis of the UGT1A1 Genotype in Hyperbilirubinemia Patients: Differences in Allele Frequency and Distribution |
Q35807302 | Association of Neonatal Hyperbilirubinemia with UGT1A1 Gene Polymorphisms: A Meta-Analysis. |
Q34257505 | Bilirubin Glucuronidation Revisited: Proper Assay Conditions to Estimate Enzyme Kinetics with Recombinant UGT1A1 |
Q51731636 | Bilirubin concentrations in thalassemia heterozygotes in university students. |
Q40468832 | Changes in the liver function tests during the attacks of familial Mediterranean fever. |
Q46825406 | Comparative genomics analysis of human sequence variation in the UGT1A gene cluster |
Q38885161 | Contribution of G71R mutation to Gilbert's syndrome phenotype in a Greek patient: A case report |
Q54571855 | Crigler-Najjar syndrome type 2. |
Q51766831 | Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family. |
Q49593574 | Effects of Gly71Arg mutation in UGT1A1 gene on neonatal hyperbilirubinemia: a systematic review and meta-analysis. |
Q37876401 | Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs |
Q92140102 | Genetic Spectrum of UGT1A1 in Korean Patients with Unconjugated Hyperbilirubinemia |
Q37775981 | Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment |
Q53572392 | Gilbert's syndrome phenotypically expressed as Crigler-Najjar syndrome type II. |
Q33867195 | Gilbert's syndrome: High frequency of the (TA)7 TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene |
Q43963256 | Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. |
Q35881663 | Identification of Promotor and Exonic Variations, and Functional Characterization of a Splice Site Mutation in Indian Patients with Unconjugated Hyperbilirubinemia. |
Q34159702 | Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency |
Q57453351 | Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer |
Q37709064 | Molecular Analysis of the UGT1A1 Gene in Korean Patients with Crigler-Najjar Syndrome Type II. |
Q64281770 | Molecular diagnosis of hereditary spherocytosis by multi-gene target sequencing in Korea: matching with osmotic fragility test and presence of spherocyte |
Q37613514 | Mutation Analysis in Crigler-Najjar Syndrome Type II-Case Report and Literature Review. |
Q26863145 | New insights in bilirubin metabolism and their clinical implications |
Q44606105 | Newborn infant with prolonged jaundice |
Q37173199 | Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? |
Q34391234 | Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events |
Q28547377 | Spectrum of UGT1A1 Variations in Chinese Patients with Crigler-Najjar Syndrome Type II |
Q38354009 | Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling. |
Q36475104 | The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions |
Q43195349 | Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity |
Q60961698 | UGT1A1 genotypes and unconjugated hyperbilirubinemia phenotypes in post-neonatal Chinese children: A retrospective analysis and quantitative correlation |
Q40426198 | UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma |
Search more.